JAMESI 50mg/850mg x 56 tabl

JAMESI 50mg/850mg x 56 tabl

In adult patients with type 2 diabetes mellitus: Jamezi is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximally tolerated dose of metformin alone or who are already being treated with a combination of sitagliptin and metformin. Jamezi is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximally tolerated dose of metformin and a sulphonylurea. Jamezi is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximally tolerated dose of metformin and a PPARγ agonist. Jamezy is also indicated as an add-on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when a stable dose of insulin and metformin alone does not provide adequate glycaemic control.Sitagliptin (as sitagliptin hydrochloride monohydrate)/Metformin (as metformin hydrochloride